Business Context and Reporting Period
Company: Atossa Genetics, Inc. (Development Stage Company)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2012
Business Overview: The Company focuses on breast cancer prevention through diagnostic tests (ForeCYTE and ArgusCYTE) and the MASCT System. In September 2012, the Company acquired assets from Acueity Healthcare, Inc., including FDA-cleared medical devices and patents, to complement its existing portfolio. The Company operates a CLIA-certified laboratory, the National Reference Laboratory for Breast Health.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2012 | Nine Months Ended Sep 30, 2012 | Balance Sheet (Sep 30, 2012) |
|---|---|---|---|
| Total Revenue | $105,576 | $383,386 | - |
| Net Loss | $(1,143,382) | $(3,374,249) | - |
| Operating Loss | $(1,135,672) | $(3,363,652) | - |
| Cash and Cash Equivalents | - | - | $418,570 |
| Restricted Cash | - | - | $250,000 |
| Total Current Assets | - | - | $885,453 |
| Total Current Liabilities | - | - | $2,290,897 |
| Accumulated Deficit | - | - | $(8,026,303) |
| Line of Credit Outstanding | - | - | $250,000 |
Note: The filing does not provide explicit gross margin percentages, but gross profit for the nine months ended September 30, 2012, was $323,517 against revenue of $383,386.
Material Changes vs. Prior Period
- Revenue Generation: The Company generated $383,386 in revenue for the nine months ended September 30, 2012, compared to $0 for the same period in 2011. This marks the beginning of commercial operations for diagnostic testing services.
- Operating Expenses: Total operating expenses increased by 65% to $3,687,169 for the nine months ended September 30, 2012, from $2,231,906 in the prior year. This increase is attributed to the launch of the MASCT System, hiring of additional staff, and increased R&D and legal expenses.
- Asset Acquisition: Intangible assets increased significantly from $40,841 to $4,703,078 due to the September 2012 acquisition of Acueity assets (patents and FDA-cleared devices).
- Liquidity: Cash and cash equivalents decreased from $1,910,821 at December 31, 2011, to $418,570 at September 30, 2012, primarily due to net cash used in operating activities of $1,967,626.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: The filing includes a "Going Concern" warning. The Company has not established an ongoing source of revenue sufficient to cover operating costs. Continued operations depend on obtaining adequate capital. Management plans to raise funds through equity sales, product sales, and short-term borrowings.
- Capital Requirements: Management estimates a need for $4 million to $6 million in additional capital to fund operations for the next 12 months. Proceeds from the subsequent IPO (November 2012) are expected to fund operations for at least the next 6 months.
- Unusual Items:
- Inventory Write-down: A loss on reduction of inventory to lower of cost or market of $29,884 was recorded for the nine months ended September 30, 2012, as the MASCT System was sold at a price substantially lower than its cost.
- Asset Purchase: The Company issued 862,500 shares of common stock and warrants valued at approximately $5.08 million in total consideration for the Acueity asset purchase.
- Legal Proceedings: A former President, Robert Kelly, filed a counterclaim seeking $450,000 in damages regarding a terminated consulting agreement. The Company believes it has a strong defense and has not recorded a liability.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $418,570 cash balance plus the $3.455 million net proceeds from the November 2012 IPO to cover the estimated $4-6 million annual burn rate.
- Revenue Sustainability: Assess the scalability of the $383,386 revenue stream, noting that product sales are currently priced below cost and rely on small-batch manufacturing.
- Acueity Integration: Confirm the timeline and capital requirements for commercializing the acquired Acueity assets, as the Company currently allocates minimal resources to them.
- Legal Exposure: Monitor the status of the Robert Kelly arbitration and litigation to determine if a liability provision becomes necessary.
- Debt Obligations: Note that the $250,000 line of credit was paid off in full on October 22, 2012 (subsequent to the balance sheet date), but verify if new debt facilities are required.